GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (FRA:0RY) » Definitions » Debt-to-Asset

Rhythm Biosciences (FRA:0RY) Debt-to-Asset : 0.02 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Rhythm Biosciences Debt-to-Asset?

Rhythm Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.02 Mil. Rhythm Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Rhythm Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €1.19 Mil. Rhythm Biosciences's debt to asset for the quarter that ended in Dec. 2023 was 0.02.


Rhythm Biosciences Debt-to-Asset Historical Data

The historical data trend for Rhythm Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Debt-to-Asset Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial - 0.02 - 0.02 0.01

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.01 0.01 0.02

Competitive Comparison of Rhythm Biosciences's Debt-to-Asset

For the Diagnostics & Research subindustry, Rhythm Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Debt-to-Asset falls into.



Rhythm Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rhythm Biosciences's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Rhythm Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (FRA:0RY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Rhythm Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (FRA:0RY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (FRA:0RY) Headlines

No Headlines